MX2015003047A - Metodos para identificar anticuerpos neutralizantes contra vih. - Google Patents
Metodos para identificar anticuerpos neutralizantes contra vih.Info
- Publication number
- MX2015003047A MX2015003047A MX2015003047A MX2015003047A MX2015003047A MX 2015003047 A MX2015003047 A MX 2015003047A MX 2015003047 A MX2015003047 A MX 2015003047A MX 2015003047 A MX2015003047 A MX 2015003047A MX 2015003047 A MX2015003047 A MX 2015003047A
- Authority
- MX
- Mexico
- Prior art keywords
- gpl20
- binding
- cell
- fusion protein
- antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382342.9A EP2706356A1 (en) | 2012-09-06 | 2012-09-06 | Methods for identifying HIV neutralizing antibodies |
| PCT/EP2013/068446 WO2014037490A1 (en) | 2012-09-06 | 2013-09-06 | Methods for identifying hiv neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015003047A true MX2015003047A (es) | 2015-07-14 |
Family
ID=46829683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003047A MX2015003047A (es) | 2012-09-06 | 2013-09-06 | Metodos para identificar anticuerpos neutralizantes contra vih. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9952218B2 (https=) |
| EP (2) | EP2706356A1 (https=) |
| JP (1) | JP6282655B2 (https=) |
| KR (1) | KR20150081255A (https=) |
| CN (1) | CN104755933B (https=) |
| AU (1) | AU2013311626A1 (https=) |
| BR (1) | BR112015004970A2 (https=) |
| CA (1) | CA2884165A1 (https=) |
| ES (1) | ES2643268T3 (https=) |
| IL (1) | IL237613A0 (https=) |
| IN (1) | IN2015DN02730A (https=) |
| MX (1) | MX2015003047A (https=) |
| PT (1) | PT2893349T (https=) |
| RU (1) | RU2015112297A (https=) |
| WO (1) | WO2014037490A1 (https=) |
| ZA (1) | ZA201502210B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166313B (zh) * | 2016-07-01 | 2018-09-07 | 浙江大学 | 一种艾滋病孕妇血液净化器 |
| CN106075626B (zh) * | 2016-07-01 | 2018-06-26 | 浙江大学 | 一种艾滋病血液净化治疗仪 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US7115262B1 (en) * | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
| WO2003040311A2 (en) * | 2001-10-25 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 |
| EP1523492A4 (en) * | 2002-07-23 | 2006-05-10 | Univ Duke | IGG FC / HIV GP120 / C3D FUSION PROTEIN |
| US8197819B2 (en) * | 2004-06-08 | 2012-06-12 | Novartis Vaccines And Diagnostics, Inc. | Env polypeptide complexes and methods of use |
| ATE471947T1 (de) * | 2005-02-03 | 2010-07-15 | Novartis Vaccines & Diagnostic | Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür |
| CN101551392A (zh) * | 2008-01-22 | 2009-10-07 | 厦门大学 | 一种检测人乳头瘤病毒中和抗体的方法 |
| CN101846679A (zh) * | 2009-03-25 | 2010-09-29 | 邢安辉 | 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法 |
| EP3957651A1 (en) * | 2010-05-21 | 2022-02-23 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
-
2012
- 2012-09-06 EP EP12382342.9A patent/EP2706356A1/en not_active Withdrawn
-
2013
- 2013-09-06 IN IN2730DEN2015 patent/IN2015DN02730A/en unknown
- 2013-09-06 WO PCT/EP2013/068446 patent/WO2014037490A1/en not_active Ceased
- 2013-09-06 RU RU2015112297A patent/RU2015112297A/ru not_active Application Discontinuation
- 2013-09-06 MX MX2015003047A patent/MX2015003047A/es unknown
- 2013-09-06 JP JP2015530408A patent/JP6282655B2/ja not_active Expired - Fee Related
- 2013-09-06 AU AU2013311626A patent/AU2013311626A1/en not_active Abandoned
- 2013-09-06 ES ES13758886.9T patent/ES2643268T3/es active Active
- 2013-09-06 CN CN201380052377.5A patent/CN104755933B/zh not_active Expired - Fee Related
- 2013-09-06 KR KR1020157008791A patent/KR20150081255A/ko not_active Withdrawn
- 2013-09-06 PT PT137588869T patent/PT2893349T/pt unknown
- 2013-09-06 EP EP13758886.9A patent/EP2893349B1/en active Active
- 2013-09-06 US US14/426,235 patent/US9952218B2/en active Active
- 2013-09-06 BR BR112015004970A patent/BR112015004970A2/pt not_active IP Right Cessation
- 2013-09-06 CA CA2884165A patent/CA2884165A1/en not_active Abandoned
-
2015
- 2015-03-08 IL IL237613A patent/IL237613A0/en unknown
- 2015-03-31 ZA ZA2015/02210A patent/ZA201502210B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2893349T (pt) | 2018-04-12 |
| WO2014037490A1 (en) | 2014-03-13 |
| IN2015DN02730A (https=) | 2015-09-04 |
| AU2013311626A1 (en) | 2015-04-30 |
| KR20150081255A (ko) | 2015-07-13 |
| CN104755933B (zh) | 2017-06-09 |
| CA2884165A1 (en) | 2014-03-13 |
| EP2706356A1 (en) | 2014-03-12 |
| EP2893349B1 (en) | 2017-08-16 |
| CN104755933A (zh) | 2015-07-01 |
| EP2893349A1 (en) | 2015-07-15 |
| JP6282655B2 (ja) | 2018-02-21 |
| ZA201502210B (en) | 2016-11-30 |
| JP2015530575A (ja) | 2015-10-15 |
| US9952218B2 (en) | 2018-04-24 |
| RU2015112297A (ru) | 2016-10-27 |
| ES2643268T3 (es) | 2017-11-21 |
| US20150233924A1 (en) | 2015-08-20 |
| IL237613A0 (en) | 2015-04-30 |
| HK1211694A1 (en) | 2016-05-27 |
| BR112015004970A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ou et al. | Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion | |
| KR102443389B1 (ko) | Sarsr-cov에 대한 항체의 검출 | |
| Groom et al. | Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome | |
| Liao et al. | Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated | |
| Fackler et al. | Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization | |
| Bego et al. | Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells | |
| AU723158B2 (en) | Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell | |
| Wang et al. | Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro | |
| US10722571B2 (en) | Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto | |
| CN110684740B (zh) | 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用 | |
| Lai et al. | Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41 | |
| US20250296985A1 (en) | Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19) | |
| Armani-Tourret et al. | Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis | |
| Jin et al. | Infection of CD4+ T lymphocytes by the human T cell leukemia virus type 1 is mediated by the glucose transporter GLUT-1: evidence using antibodies specific to the receptor's large extracellular domain | |
| Toyoda et al. | Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals | |
| US9952218B2 (en) | Methods for identifying HIV neutralizing antibodies | |
| US6251582B1 (en) | Alternative G-coupled receptors associated with retroviral entry into cells, methods of identifying the same, and diagnostic and therapeutic uses thereof | |
| Jin et al. | GLUT-1-independent infection of the glioblastoma/astroglioma U87 cells by the human T cell leukemia virus type 1 | |
| Carrillo et al. | Gp120/CD4 blocking antibodies are frequently elicited in ART-naive chronically HIV-1 infected individuals | |
| HK1211694B (en) | Methods for identifying hiv neutralizing antibodies | |
| Wu et al. | Development of an enzyme-linked immunosorbent assay based on the murine leukemia virus p30 capsid protein | |
| Schuh et al. | A surrogate cell‐based SARS‐CoV‐2 spike blocking assay | |
| RU2774782C2 (ru) | Производные слитого с Fc белка с высокой двойной активностью: противовирусной активностью в отношении ВИЧ и иммуномодулирующей активностью | |
| WO2023006267A1 (en) | A surrogate cell-based corona virus spike protein blocking assay | |
| Gapp | Mechanistic insight into the CD32-driven enhancement of HIV-1 susceptibility of resting CD4 T cells |